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Functional imaging and its application to radiotherapy (RT) is a rapidly expanding ﬁeld
with  new modalities and techniques constantly developing and evolving. As technologies
improve, it will be important to pay attention to their implementation. This review describes
the  main achievements in the ﬁeld of head and neck cancer (HNC) with particular remarks
on  the unsolved problems.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. AllKeywords:
Radiotherapy planning
Functional imaging
Metabolic imaging
PET/CT
rights reserved.
ized protocol, with careful optimization of images within the1.  Positron  Emission  Tomography/Computed
Tomography  (PET/CT)  in  RT  planning
1.1.  Introduction
PET is a signiﬁcant advance in cancer imaging with great
potential for optimizing RT planning and thereby improving
outcomes for head and neck cancer patients. The use of PET-
CT in RT planning was reviewed by an international panel.
The International Atomic Energy Agency (IAEA) organized
two synchronized and overlapping consultants’ meetings with
experts from different regions of the world in Vienna in July
∗ Corresponding author. Tel.: +34 627744220.
E-mail addresses: lapr@usal.es, lapr06@gmail.com (L.A. Pérez Roma
1507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2013.10.0072006. Nine experts and three IAEA staff evaluated the available
data on the use of PET in RT planning, and considered prac-
tical methods for integrating it into routine practice. For RT
planning, FDG was the most valuable pharmaceutical. There
was evidence for utility of PET in head and neck cancers,
with promising preliminary data in many  other cancers. The
best available approach employs integrated PET-CT images,
acquired on a dual scanner in the radiotherapy treatment
position after administration of tracer according to a standard-santa).
RT planning system and carefully considered rules for con-
touring tumour volumes. PET will play an increasing valuable
role in RT planning for a wide range of cancers.1 More  recent
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – 18F-FDG PET/CT on a patient with a supraglottic
tumour. Avid tracer uptake helps to identify a positive
lymph node located immediately lateral to the primary
tumour. Physiologic uptake in the right vocal cords besides
the fuzzy appearance of tumour borders due to low spatial
resolution of PET image hamper the accurate delineation ofreports of practical oncology and 
eview conﬁrm the value of PET/CT as an adjunct in RT plan-
ing for two main reasons: better identiﬁcation of the disease
xtent and characterization of the biological behaviour of the
isease.2
.2.  Advantages  and  disadvantages
esides the obvious improvement in patient selection for rad-
cal treatment due to exclusion of distant metastases and
f synchronous primary malignancy,3,4 there are potential
dvantages to the use of 18F-FDG-PET/CT in RT plan-
ing for HNC: reduction of inter-observer variation in
arget volume delineation,5 particularly when an insti-
utional contouring protocol is developed,6 smaller GTV
olumes,7 and more  accurate identiﬁcation of positive lymph
odes.8
The main disadvantages are the limited spatial resolu-
ion of PET images, the lower utility for identifying occult
odal metastases,8 and the false positive readings due to
nﬂammation, infection, radiation effect or physiological
ptake.2 As the spatial resolution of a CT image  is below
 mm,  a neat tumour margin is frequently displayed, par-
icularly in contrast-enhanced studies. This is not the case
ith PET images where the spatial resolution is just below
 mm.  This fact, combined with the background uptake
f contrast due to physiologic processes, contribute to the
uzzy appearance of tumour edges. PET/CT does not add
alue over CT or MRI  for T staging9 and superﬁcial tumour
pread in HNC is often missed.7 Therefore, a limitation
f the PET image  is its inability to deﬁne depth of inva-
ion and relation of tumours to neighbouring structures
Figure 1).
Spatial resolution of PET limits its utility to characterize
he micro-regional distribution of tumours phenotype. Pre-
linical studies have shown discrepancies between imaging
ith a small-animal PET scanner with a spatial resolution of
.7 mm and the underlying microscopic reality represented
y autoradiography.10 Such a discrepancy means the macro-
copic assessment of tumours with molecular imaging might
ot necessarily reﬂect their micro-regional distribution.11
any  micro-regional tumour areas are likely to coexist within
ne clinical PET voxel. Negative scan ﬁndings cannot, there-
ore, exclude the presence of microscopic tissue involvement,
nd precise anatomic location of the signal can be difﬁcult.
espite these inherent weaknesses, PET imaging has proven
o generate quantitative tumour maps that accurately reﬂect
he underlying microscopic reality in an animal model with a
linical realistic image  contrast.12 As the set-up tolerance is up
o 3 mm for patients with HNC immobilized in thermoplastic
asks, caution should also be given to dose prescriptions to a
oxel of approximately 4 mm size as its precise location intra-
r inter-fraction cannot be assured. Heterogeneous dose pre-
criptions adapted by voxel may not be possible with current
elivery systems due to limited dose distribution spatial res-
lution and target localization inaccuracies related to set-up
nd organ motion errors. Furthermore, the microenvironment
f treated and untreated tumours changes with time adding
ncertainty to voxel oriented dose distributions.13,14
Accurate assessment of primary tumour size, extent,
nd depth of invasion is pertinent to planning the mosttumour contours.
appropriate local treatment. The most appreciated utility of
PET/CT is the detection of an unknown primary in situations
where there is a strong clinical suspicion of a primary despite
a negative exploration and biopsy. It has been demonstrated
that primary tumour detection was signiﬁcantly higher with
PET or PET/CT compared with CT or magnetic resonance imag-
ing (MRI) due to a higher sensitivity.15
1.3.  The  segmentation  problem
Before PET-based GTVs can reliably and reproducibly be
incorporated into high-precision RT planning, operator-
independent segmentation tools have to be developed and
validated.16,17 Simple visual interpretation of the PET signal
is most commonly applied but is highly operator-dependent,
as it is susceptible to the window-level settings of the
images and to interpretation discrepancies.5 Visual inter-
pretation has signiﬁcant inter and intra-observer variations
which may be improved when criteria for tissue deﬁnition
is included during interpretation.5 Variability of the GTV
based on PET images (GTVPET) delineation could be avoided
adopting more  objective methods, such as iso-contouring
based on a ﬁxed standardized uptake value (SUV), or rela-
tive thresholds such as a proportion of the maximum SUV
d rad378  reports of practical oncology an
(SUVmax) in the tumour. Several reports have been published
which compared different ﬁxed or relative thresholding as
GTVPET delineation method.18,19 Metabolic treatment volumes
deﬁned in relation to SUVmax are prone to variability between
centres because SUVmax is highly dependent on contrast
recovery and noise properties that vary across scanners and
reconstructive protocols. Daisne et al. described a variable
threshold adaptive to the signal-to-background ratio (RS/B) in
their study on laryngeal cancer patients.20 Subsequently, this
group validated their results against volumetric histopatho-
logy for primary tumours of the larynx–hypopharynx.7 Some
authors have introduced gradient-based segmentation tools
validated against phantoms and macroscopic specimens of
laryngeal tumours (Geets X 2007),21 background-subtracted
relative-threshold level (RTL) method,22 fuzzy locally adaptive
Bayesian (FLAB) method,23 and iterative TrueX algorithm.24
Few segmentation algorithms have been clinically or histolog-
ically validated and this is a source of uncertainty for volume
deﬁnition.
1.4.  Sensitivity  and  speciﬁcity
How the sensitivity and speciﬁcity of a particular imaging
modality inﬂuence the radiation planning process depends on
the underlying objective of the treatment. If the objective is
to avoid missing a tumour at any expense, a highly sensitive
approach needs to be selected. Such a selection will result in
a lower speciﬁcity and in the inclusion of non-neoplastic tis-
sue in the target volume. However, this approach reduces the
likelihood of missing neoplastic cells. If, on the other hand,
the aim is to avoid including non-neoplastic cells in the target
volume to protect normal tissue, a highly speciﬁc approach
needs to be elected. However, such an approach reduces sen-
sitivity and increases the risk for missing tumour cells. When
18F-FDG PET/CT is introduced with treatment planning pur-
poses, its sensitivity and speciﬁcity need to be compared
with those of the standard test, this is, CT, and its poten-
tial impact on treatment planning needs to be determined.
CT and 18F-FDG PET/CT perform with comparable diagnostic
accuracies.25 A meta-analysis has summarized the available
literature on the use of 18FDG-PET for the assessment of the
cervical lymph node status in squamous cell HNC. According
to Kyzas et al., sensitivity and speciﬁcity of FDG PET were 80%
and 86%, respectively, and of conventional diagnostic tests
were 75% and 79%, respectively.8 The detection of retropha-
ryngeal lymph node metastases is particularly advantageous
with FDG PET-CT. Chu et al. showed that adding FDG PET-
CT to the conventional CT/MRI work up increased diagnostic
efﬁcacy, both sensitivity (89% vs 62%) and speciﬁcity (86% vs
60%).26
A potentially interesting use of 18F-FDG PET is staging for
patients with nodes found negative (node negative) by other
imaging modalities, in whom the issue could be to avoid treat-
ing neck nodes if an 18F-FDG PET examination is negative.
However, data have indicated that in the node-negative neck,
the sensitivity of 18F-FDG PET, compared with that of exami-
nation of a pathologic specimen after neck node dissection, is
only about 70%.25 PET/CT in its current stage, mainly impeded
by a low spatial resolution, does not appear to offer an advan-
tage in staging the clinically N0 neck due to high rates ofiotherapy 1 8 ( 2 0 1 3 ) 376–382
false positives and limited sensitivity for small metastatic
deposits and, consequently, it is not likely to be superior for
the selection of the target volume in neck lymph nodes.27 The
management of the N0 neck should not be based on PET-CT
ﬁndings alone.28 Furthermore, diverse PET segmentation tools
identify a variable proportion of nodes classiﬁed as enlarged or
marginally enlarged on CT, precluding its implementation in
routine practice for neck volume deﬁnition until proper vali-
dation could be accomplished.29
1.5.  PET  derived  volumes  for  dose  escalation  studies
Due to the sub-optimal outcome for a signiﬁcant proportion
of patients with HNC, PET derived GTVs are an attractive
target for dose escalation. The dose required to overcome
radioresistance within the target volume is unknown. Biolog-
ical modelling could guide the dose planning optimization
process matching the heterogeneous dose distribution to
the pretended radioresistant tumour subvolumes.30,31 Current
treatment prescriptions are already close to patient tolerance
making it difﬁcult to expand the therapeutic window through
this strategy. Some clinical studies have been published eval-
uating the outcome of 18F-FDG-PET based dose escalation.32
18F-FMISO PET has also been used to deﬁne a hypoxic sub-
volume and theoretical planning studies have demonstrated
the potential to dose-escalate to this sub-volume.33,34 One
of the limitations of 18F-FMISO imaging in this setting may
be its temporal variability. Nehmeh et al.35 have shown in a
study with 14 evaluable patients who underwent two base-
line 18F-FMISO scans 3 days apart, a voxel by voxel analysis of
putative hypoxic areas revealed a strong correlation across the
two time points in only 6 patients. To date, no clinical studies
have been published with outcome of dose escalation to 18F-
FMISO-deﬁned volumes. Troost et al.16,17 demonstrated that
high proliferative tumour subvolumes, as deﬁned by 18F-FLT
PET, can provide the basis for an IMRT plan with dose escala-
tion within these regions.
1.6.  PET-image  voxel-guided  RT
Dose painting by numbers is a voxel-level prescription
of dose based on a mathematical transformation of the
image intensity of individual pixels. Quantitative use of
images to decide both where and how to delivery radia-
tion therapy in an individual case is also called theragnostic
imaging. Dose painting targets are imaging surrogates for
cellular or microenvironmental phenotypes associated with
poor radioresponsiveness.36 Planning and feasability studies
and preliminary tolerance studies have been published.37–39
Feasability studies using deformable image  co-registration in
three-phase adaptive dose-painting-by-numbers for head and
neck cancer have been published.40 Irradiation of smaller tar-
get volumes might have contributed to mild acute toxicity
with no measurable decrease in tumour control.
1.7.  PET-image  as  a  biomarker  with  prognostic  and/or
predictive  value
18F-FDG-PET imaging might identify patients who  are less
likely to respond to current treatment strategies and may
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eneﬁt from alternative treatments, dose escalation, or early
alvage options. Monitoring of early response during treat-
ent could allow treatment modiﬁcation or adaptation and
his has been shown in a proof-of-principle study by Geets
t al.41 Several published studies have demonstrated this
ole using baseline 18F-FDG-PET parameters,42–49 or 18F-FDG-
ET imaging acquired 2–4 months following completion of
reatment.50–53 The optimum timing of 18F-FDG-PET imag-
ng following treatment is uncertain due to 18F-FDG uptake
n non-malingnant inﬂammatory tissue which complicates
nterpretation.54 Several studies have shown that the level
f hypoxia depicted by 18F-FMISO PET before treatment cor-
elates with loco-regional failure.55,56 A change in 18F-FLT
ptake early during radiotherapy of chemoradiotherapy is a
trong indicator for long-term outcoume.13,14
.8.  Clinical  implementation  and  standardization
espite a decade of activity in this ﬁeld, functional imaging
s yet to be implemented into routine clinical practice. The
eason for this relates to most data being generated from
ingle institution series with variations in imaging modal-
ty, sequence acquisition, data processing and analysis tools.
he next challenge is implementing PET imaging and tack-
ing the associated uncertainties. As preliminary ﬁndings are
alidated in larger studies, so attention to standardization
f protocols and image  processing and data analysis must
ccur. This is necessary not only for implementing ﬁndings
rom studies performed at other institutions but, most impor-
ant, in the design for multicenter trials which must include
igorous quality assurance.57 In the image  acquisition pro-
ess of PET-CT for RT planning, radiation oncologists and
uclear medicine physicians need to work together in close
ollaboration. This partnership is crucial due to the enormous
rganizational effort required and to assure correct interpre-
ation of the imaging studies. Medical physicists also play an
ssential role due to their involvement in standardizing the
rocess and in quality control. For all these reasons, mul-
idisciplinary collaboration is absolutely essential if PET-CT
maging is to fulﬁl its potential for RT planning. Recommenda-
ions on the use of PET-CT in RT planning have been published
reviously, including those described by the European Soci-
ty of Radiation Oncology (ESTRO) and European Association
f Nuclear Medicine (EANM), in an attempt to standardize
ET image  acquisition, processing and reporting.58 However,
hese are yet to be fully adopted. Consensuated recommenda-
ions by a working party of the Spanish of Radiation Oncology,
uclear Medicine, and Medical Physics have been also pub-
ished recently in these Reports.59
.9.  Conclusion
ET/CT is being used at present for volume deﬁnition and as a
iomarker. Studies with multiple tracers obtained at different
ime points are testing the potential value of this modality
or stratiﬁcation of patients and RT dose escalation. Never-
heless, some intrinsic limitations as coarse spatial resolution
nd false positive readings besides methodological problemstherapy 1 8 ( 2 0 1 3 ) 376–382 379
like segmentation algorithm of choice and lack of standard-
ization could hamper its clinical implementation.
2.  MRI  for  RT  planning
MRI  can add to the radiotherapy treatment planning (RTP) pro-
cess by providing excellent and improved characterization of
soft tissues compared with CT and better spatial resolution
compared with PET. MRI can beneﬁt treatment planning by
improving target volume delineation and assessment of plan-
ning margins in many  cancer subtypes in sites such as the
brain, spinal cord, soft tissues of the head and neck, trunk
and limbs.60 Techniques such as dynamic contrast enhanced
MRI  (DCEMRI) and diffusion MRI to better characterize tis-
sue and tumour regions, BOLD technique (Blood Oxygen Level
Dependent) for hypoxic areas, as well as ultrafast volumetric
cine MR sequences to deﬁne temporal changes of target and
organ at risk have all increased the scope and utility of MRI
for treatment planning. Information from these MR  develop-
ments may permit treatment individualization, strategies of
dose escalation and image-guided radiotherapy.60
Furthermore, functional MRI is an important tool to under-
stand the dynamics of tumour response to radiotherapy
with potential application for adapting and individualizing
the treatment. In order to adapt biological models to data
from functional imaging, treatment, response and radio resis-
tant volumes must be surveyed. This goal can be achieved
with ADC maps (apparent diffusion coefﬁcient) from dif-
fusion weighted MRI (DWMRI). Once a predictive model of
tumour response based on functional image  is built up, a new
optimization method will be achievable. The integration of
functional MRI in the radiotherapy planning and treatment
response evaluation has attracted the interest of different
research groups worldwide,61–65 up to the assembly of hybrid
linac-MRI machines.66
2.1.  DWMRI/ADC
DWMRI measures the diffusion of protons in a medium. It is
based in the attenuation of the signal according to Stejskal
& Tanner model.67 Tumour cells are bigger than normal cells
and the extracellular volume is smaller in tumour regions,
then the freedom of movements of protons in tumour regions
is restricted. The logarithm of the signal attenuation is a
function of the applied gradient, gap between pulses of gradi-
ent, and the pulse duration. Varying these parameters during
acquisition, the apparent diffusion coefﬁcient can be calcu-
lated for each voxel.
Fig. 2 shows the increment in ADC value as dose is delivered
in seven different lesions of two patients (2 tumour lessions
and 5 nodes) at different time points along the treatment. The
main advantages of this technique for tumour response eval-
uation are the direct correlation between the measured ADC
and tumour cell density, the quantitative nature of the ADC
parameter that allows comparison between different centres,
the ubiquity and availability of MR scans and the non-invasive
nature of the procedure, not requiring contrast agent. Geomet-
rical distortion, as can be observed in Fig. 3 and noisy images
due to movement  artefacts are the main disadvantages. Work
380  reports of practical oncology and rad
Fig. 2 – Two patient of ARTFIBio project were  monitored
during treatment. In this ﬁgure, the increment in the
average ADC of different target volumes (5 nodes and 2
primary tumours) during treatment in the low distorted
region is shown.
Fig. 3 – Distorted ADC map  overlapping computed
tomography in sagittal view from ARTFIBio project. Crosses
rindicate analyzed slices in Fig. 2.
is in progress to reduce geometrical distortion by using dif-
ferent diffusion weighted techniques, as DW-EPI68 (diffusion
weighted-echo planar imaging) or by using deformable regis-
tration methods (Fig. 3).
2.2.  BOLD  MRI
Contrast in BOLD techniques is due to the changes in
the paramagnetic momentum between oxyhemoglobine and
deoxyhemoglobine.69 An increased rate of metabolic oxygen
consumption generates an increase of concentration of deoxy-
hemoglobin (common in tumours and cerebral activity). This
non-invasive technique allows the in vivo measurement of
oxygenation distribution, not only previously the treatment,
but also the evolution along the treatment, with no need of
contrast agent. Information losses can be produced because
movement  artefacts.iotherapy 1 8 ( 2 0 1 3 ) 376–382
2.3.  DCE  MRI
Dynamic contrast enhance MRI has been proposed for sev-
eral authors for treatment monitoring70 and for measurement
of oxygenation distribution.71 The main problem is the com-
plexity of the data analysis and the correspondence between
measurement and biological parameters. Another disadvan-
tage is the necessity of contrast agent.
2.4.  Conclusions
The combined information from different imaging modalities
can improve radiotherapy treatment, not only through bet-
ter target volume delineation, but also adapting treatment to
real tumour dynamics during the treatment. ADC maps can be
used not only for treatment planning, but also for quantiﬁca-
tion of tumour response voxel by voxel. The main weakness
of this method is registration of the highly distorted images
from DWMRI and great efforts are being carried out by sci-
entiﬁc community to overcome this problem. Even more,  the
joint use of MRI diffusion data, DCEMRI and PET/CT can be
useful for delimiting the tumour hypoxic areas. Variation of
the hypoxic areas can be monitorized also during treatment
by DCEMRI. Treatment response monitorization by functional
imaging might be the way to implement biological adaptive
radiotherapy.
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